Using Anti-Müllerian Hormone to Protect Ovaries During Cancer Treatment and Transplant
Anti-Mullerian hormone for preserving ovarian function before administration of gonadotoxic therapies or after transplantation of cryopreserved tissue.
This project will try giving the ovarian hormone AMH together with cultured blood-vessel cells to protect ovarian tissue and preserve fertility in girls and women facing chemotherapy or ovarian tissue transplantation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11333832 on NIH RePORTER |
What this research studies
If you need chemotherapy that can harm your ovaries or you have frozen ovarian tissue for later transplant, this work aims to protect your ovarian tissue and eggs. The researchers combine cultured vascular cells to speed blood flow into transplanted tissue with Anti-Müllerian Hormone (AMH) to slow premature follicle activation. They will test these approaches in laboratory and transplant models and move toward approaches that could be used with patients. The goal is to improve graft survival and keep more of your ovarian reserve after treatment or transplantation.
Who could benefit from this research
Good fit: Girls and women facing gonadotoxic chemotherapy who cannot undergo ovarian stimulation, and people with cryopreserved ovarian tissue planning autotransplantation, are the most likely candidates.
Not a fit: People without ovarian tissue at risk (for example postmenopausal women) or those whose infertility is unrelated to ovarian follicle loss are unlikely to benefit.
Why it matters
Potential benefit: If successful, this approach could preserve ovarian function and fertility, reducing the risk of premature ovarian failure after chemotherapy or tissue transplant.
How similar studies have performed: Preclinical work shows cultured vascular cells can improve graft blood flow and AMH can slow follicle activation, but combining these methods for human ovarian protection is experimental and not yet proven in patients.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: James, Daylon J — Weill Medical Coll of Cornell Univ
- Study coordinator: James, Daylon J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.